Immunogenicity of quadrivalent human papillomavirus vaccine among Alaska Native children aged 9–14 years at 5 years after vaccination

Bionca M. Davis,Ian Blake,Gitika Panicker,Elissa Meites,Gail Thompson,Jesse Geis,Dana Bruden,Marc Fischer,Rosalyn Singleton,Elizabeth R. Unger,Lauri E. Markowitz,Michael G. Bruce

DOI: https://doi.org/10.1016/j.vaccine.2024.04.033

IF: 4.169

2024-04-18

Vaccine

Abstract:Background Persistent human papillomavirus (HPV) infection can cause anogenital and oropharyngeal cancers. Many HPV infections and HPV-associated cancers are vaccine-preventable. Studies suggest long-term persistence of vaccine-induced antibodies. However, data are limited among Alaska Native people. Methods During 2011–2014, we enrolled Alaska Native children aged 9–14 years who received a 3-dose series of quadrivalent HPV vaccine (4vHPV). We collected sera at 1 month and 1, 2, 3, and 5 years post-vaccination to evaluate trends in type-specific immunoglobulin G antibody concentrations for the 4vHPV types (HPV 6/11/16/18). Results All participants (N = 469) had detectable antibodies against all 4vHPV types at all timepoints post-vaccination. For all 4vHPV types, antibody levels peaked by 1 month post-vaccination and gradually declined in subsequent years. At 5 years post-vaccination, antibody levels were higher among children who received 4vHPV at a younger age. Conclusions Alaska Native children maintained antibodies against all 4vHPV types at 5 years post-vaccination.

immunology,medicine, research & experimental